Laekna’s LAE002(Afuresertib) + LAE001 Receives FDA Approval for P-III Trial Protocol to Treat Prostate Cancer
Shots:
- Laekna’s combination therapy LAE201 (LAE002 + LAE001), has received US FDA approval for P-III trial protocol to treat mCRPC following SoC treatment
- P-III trial design has been discussed with FDA based on P-II study data, shown reassuring anti-tumor activity and safety profile with mrPFS of 8.1mos. to treat mCRPC patients (n=40) progressed on 1–3L of standard treatments (at least 1L of abiraterone or 2L AR antagonists)
- LAE002 (afuresertib), is an AKT inhibitor and LAE001, is CYP17A1/CYP11B2 dual inhibitor
Ref: Laekna | Image: Laekna
Related News:- Laekna Acquires Exclusive WW Rights of Two Oncology Clinical Stage Candidates from Novartis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
